A Study of IBI351 in Healthy Subjects

Study Overview
=================
Brief Summary
-----------------
This is a randomized, open-label, two-cycle clinical study to evaluate the drug interaction, food effect and pharmacokinetics of IBI351 and esomeprazole in healthy subjects. A total of two cohorts were planned to be enrolled in each cohort. Cohort 1: This cohort investigated the effect of esomeprazole on the pharmacokinetics of IBI351 in healthy subjects. Cohort 2: This cohort investigated the effect of food on the pharmacokinetics of IBI351 in healthy subjects.

Official Title
-----------------
A Randomized, Open-label, Two-cycle Clinical Study to Evaluate the Drug Interaction, Food Effect and Pharmacokinetics of IBI351 With Esomeprazole in Healthy Subjects

Conditions
-----------------
Healthy Subjects

Intervention / Treatment
-----------------
* Drug: IBI351
* Drug: Esomeprazole


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: voluntarily sign the informed consent form before the trial, fully understand the content, process and possible adverse reactions of the trial, and be able to complete the study according to the requirements of the trial protocol. healthy male subjects aged 18 to 45 years (including both ends) at the time of signing informed consent. body weight is not less than 50 kg, and body mass index (BMI) is within the range of 19   26 kg/m2 (including cut-off value). Exclusion Criteria: have taken any products containing alcohol or have a positive alcohol breath test (≥ 20 mg/100 ml) within 24 hours before taking study medication. hepatitis B surface antigen HBsAg positive. hepatitis C virus antibody positive. positive AIDS antigen/antibody or Treponema pallidum antibody

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: IBI351<br>This cohort investigated the effect of food on the pharmacokinetics of IBI351 in healthy subjects. In a double-crossover design, subjects were enrolled and randomly divided into two test groups A and B. Group A: IBI351 was orally administered to subjects in this group on an empty stomach on Day 1, followed by a high-fat meal on Day 4. Group B: IBI351 was orally administered to subjects in this group after a high-fat meal on Day 1 followed by an empty stomach on Day 4. | Drug: IBI351<br>* IBI351 is administered orally<br>|
| Other: IBI351+Esomeprazole<br>Enrolled subjects were orally administered IBI351 with recommended dose on an empty stomach. Esomeprazole were administered orally. | Drug: IBI351<br>* IBI351 is administered orally<br>Drug: Esomeprazole<br>* Esomeprazole is administered orally<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| maximum concentrations (Cmax ) for plasma |  | approximately 10 days after first dose | 
| area under the curve from time 0 to infinity(AUC0-inf) for plasma |  | approximately 10 days after first dose | 
| area under the curve from time 0 to the last time point (AUC0-t) for plasma |  | approximately 10 days after first dose | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| time-to-maximum concentration (Tmax) for total plasma |  | approximately 10 days after first dose | 
| half-life (t1/2) for total plasma |  | approximately 10 days after first dose | 
| apparent clearance (CL/F) for total plasma |  | approximately 10 days after first dose | 
| the time prior to the first measurable (non-zero) concentration （tlag） |  | approximately 10 days after first dose | 
| apparent volume of distribution(Vz/F) for total plasma |  | approximately 10 days after first dose | 
| adverse events |  | approximately 10 days after first dose | 
| number of participants with abnormal ECG readings |  | approximately 10 days after first dose | 
| number of participants with abnormal hematology test results |  | approximately 10 days after first dose | 
| number of participants with abnormal chemisty test results |  | approximately 10 days after first dose | 
| number of participants with abnormal vital signs |  | approximately 10 days after first dose | 
| number of participants with abnormal physical examination |  | approximately 10 days after first dose |